Laetitia Marisa1, Magali Svrcek1, Ada Collura1, Etienne Becht1, Pascale Cervera1, Kristell Wanherdrick1, Olivier Buhard1, Anastasia Goloudina1, Vincent Jonchère1, Janick Selves1, Gerard Milano1, Dominique Guenot1, Romain Cohen1, Chrystelle Colas1, Pierre Laurent-Puig1, Sylviane Olschwang1, Jérémie H Lefèvre1, Yann Parc1, Valérie Boige1, Côme Lepage1, Thierry André1, Jean-François Fléjou1, Valentin Dérangère1, François Ghiringhelli1, Aurélien de Reynies1, Alex Duval1. 1. Programme "Cartes d'Identité des Tumeurs," Ligue Nationale Contre le Cancer, Paris, France; INSERM, UMRS 938 - Centre de Recherche Saint-Antoine, Equipe "Instabilité des Microsatellites et Cancers," Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France; Sorbonne Université, UPMC Univ Paris 06, Paris, France; AP-HP, Hôpital Saint-Antoine, Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre de Recherche en Cancérologie de Toulouse, UMR 1037 INSERM - Université Toulouse III, Department of Pathology, CHU, Toulouse, France; Laboratoire d'Oncopharmacologie, EA 3836, Centre Antoine Lacassagne, Nice, France; INSERM, U682, Développement et Physiopathologie de l'Intestin et du Pancréas, Strasbourg, France; AP-HP, Hôpital Saint-Antoine, Service d'Oncologie Médicale, Paris, France; AP-HP, Laboratoire d'oncogénétique et d'Angiogénétique, GH Pitié-Salpétrière, Paris, France; INSERM, Unité Mixte de Recherche, Paris Sorbonne Cité, Université Paris Descartes, Paris, France; Aix Marseille Univ, INSERM, GMGF, Marseille, France and RGDS, HP Clairval, Marseille, France; AP-HP, Service de Chirurgie Générale et Digestive, Hôpital Saint-Antoine, Paris, France; Department of Oncologic Medicine, Gustave-Roussy, Villejuif, France; Université Paris Descartes, Paris Sorbonne Cité INSERM UMR-S775, Paris, France; INSERM, Burgundy Cancer Registry, U866, Burgundy University, Dijon University Hospital, BP 87900?21079 Dijon, France; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France; INSERM, UMR866, Burgundy University; Platform of transfer in oncology, Burgundy University, Centre Georges-François Leclerc, Dijon, France.
Abstract
Background: Immune checkpoint (ICK) expression might represent a surrogate measure of tumor-infiltrating T cell (CTL) exhaustion and therefore be a more accurate prognostic biomarker for colorectal cancer (CRC) patients than CTL enumeration as measured by the Immunoscore. Methods: The expression of ICKs, Th1, CTLs, cytotoxicity-related genes, and metagenes, including Immunoscore-like metagenes, were evaluated in three independent cohorts of CRC samples (260 microsatellite instable [MSI], 971 non-MSI). Their associations with patient survival were analyzed by Cox models, taking into account the microsatellite instability (MSI) status and affiliation with various Consensus Molecular Subgroups (CMS). PD-L1 and CD8 expression were examined on a subset of tumors with immunohistochemistry. All statistical tests were two-sided. Results: The expression of Immunoscore-like metagenes was statistically significantly associated with improved outcome in non-MSI tumors displaying low levels of both CTLs and immune checkpoints (ICKs; CMS2 and CMS3; hazard ratio [HR] = 0.63, 95% confidence interval [CI] = 0.43 to 0.92, P = .02; and HR = 0.55, 95% CI = 0.34 to 0.90, P = .02, respectively), but clearly had no prognostic relevance in CRCs displaying higher levels of CTLs and ICKs (CMS1 and CMS4; HR = 0.46, 95% CI = 0.10 to 2.10, P = .32; and HR = 1.13, 95% CI = 0.79 to 1.63, P = .50, respectively), including MSI tumors. ICK metagene expression was statistically significantly associated with worse prognosis independent of tumor staging in MSI tumors (HR = 3.46, 95% CI = 1.41 to 8.49, P = .007). ICK expression had a negative impact on the proliferation of infiltrating CD8 T cells in MSI neoplasms (median = 0.56 in ICK low vs median = 0.34 in ICK high, P = .004). Conclusions: ICK expression cancels the prognostic relevance of CTLs in highly immunogenic colon tumors and predicts a poor outcome in MSI CRC patients.
Background: Immune checkpoint (ICK) expression might represent a surrogate measure of tumor-infiltrating T cell (CTL) exhaustion and therefore be a more accurate prognostic biomarker for colorectal cancer (CRC) patients than CTL enumeration as measured by the Immunoscore. Methods: The expression of ICKs, Th1, CTLs, cytotoxicity-related genes, and metagenes, including Immunoscore-like metagenes, were evaluated in three independent cohorts of CRC samples (260 microsatellite instable [MSI], 971 non-MSI). Their associations with patient survival were analyzed by Cox models, taking into account the microsatellite instability (MSI) status and affiliation with various Consensus Molecular Subgroups (CMS). PD-L1 and CD8 expression were examined on a subset of tumors with immunohistochemistry. All statistical tests were two-sided. Results: The expression of Immunoscore-like metagenes was statistically significantly associated with improved outcome in non-MSI tumors displaying low levels of both CTLs and immune checkpoints (ICKs; CMS2 and CMS3; hazard ratio [HR] = 0.63, 95% confidence interval [CI] = 0.43 to 0.92, P = .02; and HR = 0.55, 95% CI = 0.34 to 0.90, P = .02, respectively), but clearly had no prognostic relevance in CRCs displaying higher levels of CTLs and ICKs (CMS1 and CMS4; HR = 0.46, 95% CI = 0.10 to 2.10, P = .32; and HR = 1.13, 95% CI = 0.79 to 1.63, P = .50, respectively), including MSI tumors. ICK metagene expression was statistically significantly associated with worse prognosis independent of tumor staging in MSI tumors (HR = 3.46, 95% CI = 1.41 to 8.49, P = .007). ICK expression had a negative impact on the proliferation of infiltrating CD8 T cells in MSI neoplasms (median = 0.56 in ICK low vs median = 0.34 in ICK high, P = .004). Conclusions: ICK expression cancels the prognostic relevance of CTLs in highly immunogenic colon tumors and predicts a poor outcome in MSI CRCpatients.
Authors: John D Klement; Amy V Paschall; Priscilla S Redd; Mohammed L Ibrahim; Chunwan Lu; Dafeng Yang; Esteban Celis; Scott I Abrams; Keiko Ozato; Kebin Liu Journal: J Clin Invest Date: 2018-11-05 Impact factor: 14.808
Authors: Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song Journal: Gut Date: 2018-02-06 Impact factor: 23.059
Authors: Chunwan Lu; Dafeng Yang; John D Klement; Il Kyu Oh; Natasha M Savage; Jennifer L Waller; Aaron H Colby; Mark W Grinstaff; Nicholas H Oberlies; Cedric J Pearce; Zhiliang Xie; Samuel K Kulp; Christopher C Coss; Mitch A Phelps; Thomas Albers; Iryna O Lebedyeva; Kebin Liu Journal: Cancer Immunol Res Date: 2019-01-04 Impact factor: 11.151
Authors: Tomotaka Ugai; Jennifer Borowsky; Marios Giannakis; Shuji Ogino; Juha P Väyrynen; Mai Chan Lau; Naohiko Akimoto; Sara A Väyrynen; Melissa Zhao; Rong Zhong; Koichiro Haruki; Andressa Dias Costa; Kenji Fujiyoshi; Kota Arima; Kana Wu; Andrew T Chan; Yin Cao; Mingyang Song; Charles S Fuchs; Molin Wang; Jochen K Lennerz; Kimmie Ng; Jeffrey A Meyerhardt; Jonathan A Nowak Journal: Cancer Immunol Immunother Date: 2021-09-16 Impact factor: 6.630
Authors: Jennifer Borowsky; Koichiro Haruki; Mai Chan Lau; Andressa Dias Costa; Jochen K Lennerz; Marios Giannakis; Jonathan A Nowak; Shuji Ogino; Juha P Väyrynen; Tomotaka Ugai; Kota Arima; Annacarolina da Silva; Kristen D Felt; Melissa Zhao; Carino Gurjao; Tyler S Twombly; Kenji Fujiyoshi; Sara A Väyrynen; Tsuyoshi Hamada; Kosuke Mima; Susan Bullman; Tabitha A Harrison; Amanda I Phipps; Ulrike Peters; Kimmie Ng; Jeffrey A Meyerhardt; Mingyang Song; Edward L Giovannucci; Kana Wu; Xuehong Zhang; Gordon J Freeman; Curtis Huttenhower; Wendy S Garrett; Andrew T Chan; Barbara A Leggett; Vicki L J Whitehall; Neal Walker; Ian Brown; Mark Bettington; Reiko Nishihara; Charles S Fuchs Journal: Clin Cancer Res Date: 2021-02-25 Impact factor: 13.801